Tiziana Life Sciences is a NASDAQ listed (NASDAQ:TLSA) clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative diseases and gastrointestinal diseases. Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
Our mission is to bring breakthrough therapies with the aim of treating SPMS, Crohn's Disease and KRAS+ NSCLC and optimizing health outcomes.
We are developing transformational formulation technologies, enabling to switch from traditional routes to alternative routes of immunotherapy to facilitate local site of action. For example, nasal, oral and inhalation administrations are to target neurodegenerative, gastrointestinal and lung diseases, respectively. We believe, if we succeed in these alternative routes of immunotherapies that has the potential to change the way immunotherapies are currently conducted.
View our latest investor presentation Investor Deck
Tiziana has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group. The reorganisation will be achieved by a scheme of arrangement under Part 26 of the Companies Act 2006.